补充雷洛昔芬对绝经后妇女血压和载脂蛋白的影响：系统回顾与元分析》。

IF 2.5 3区生物学 Q3 BIOCHEMISTRY & MOLECULAR BIOLOGY

Prostaglandins & other lipid mediators Pub Date : 2024-09-27 DOI:10.1016/j.prostaglandins.2024.106912

Nooshin Noshadi , Atefeh Bonyadian , Salehe Zarian , Fatemeh Kazemi , Melika Darzi , Farzaneh Akhavan Tabib , Mahdieh Abbasalizad-Farhangi , Beitullah Alipour , Sarehnaz Aghili

{"title":"补充雷洛昔芬对绝经后妇女血压和载脂蛋白的影响：系统回顾与元分析》。","authors":"Nooshin Noshadi , Atefeh Bonyadian , Salehe Zarian , Fatemeh Kazemi , Melika Darzi , Farzaneh Akhavan Tabib , Mahdieh Abbasalizad-Farhangi , Beitullah Alipour , Sarehnaz Aghili","doi":"10.1016/j.prostaglandins.2024.106912","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Several studies indicated the ameliorating effects of raloxifene supplementation on apolipoproteins and blood pressure, although others have conflicting findings. Therefore, the present study was conducted in order to accurately and definitively understands the effect of raloxifene on apolipoprotein AI (Apo-AI), apolipoprotein B (APoB), lipoprotein (a) (Lp (a)), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in postmenopausal women.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted using scientific databases including PubMed, Scopus, Embase, and Web of Science and the Cochrane Library, through May 2024. The quality of studies was assessed using Cochrane tool. Random-effects meta-analysis was used to pool standardized mean differences (SMD) and 95 % CI for the outcomes.</div></div><div><h3>Results</h3><div>Twenty trials, with interventions ranging from 6 to 144 weeks and 2825 participants, were included. Raloxifene supplementation demonstrated significant reductions in ApoB (SMD: −0.92; 95 % CI: −1.49 to −0.35; P = 0.001), and Lp (a) (SMD: −0.25; 95 % CI: −0.39 to −0.11; P < 0.001) while increasing Apo-AI levels (SMD: 0.29; 95 % CI: 0.22–0.36; P < 0.001). Conversely, no significant effects were observed on SBP (WMD: −0.49 mmHg; 95 % CI: −3.01–2.04; P = 0.706), and DBP (WMD: −0.81 mmHg; 95 % CI: −4.04–2.41; P = 0.621). Moreover, subgroup analysis indicated that raloxifene significantly decreased DBP in studies with intervention durations of >12 weeks.</div></div><div><h3>Conclusions</h3><div>This meta-analysis has shown that raloxifene supplementation may have beneficial effects on apolipoproteins in postmenopausal women. Future studies are needed to investigate the effect of raloxifene on health status in in postmenopausal women.</div></div>","PeriodicalId":21161,"journal":{"name":"Prostaglandins & other lipid mediators","volume":"175 ","pages":"Article 106912"},"PeriodicalIF":2.5000,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The effect of raloxifene supplementation on blood pressure and Apo-lipoproteins in postmenopausal women: A systematic review and meta-analysis\",\"authors\":\"Nooshin Noshadi , Atefeh Bonyadian , Salehe Zarian , Fatemeh Kazemi , Melika Darzi , Farzaneh Akhavan Tabib , Mahdieh Abbasalizad-Farhangi , Beitullah Alipour , Sarehnaz Aghili\",\"doi\":\"10.1016/j.prostaglandins.2024.106912\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Several studies indicated the ameliorating effects of raloxifene supplementation on apolipoproteins and blood pressure, although others have conflicting findings. Therefore, the present study was conducted in order to accurately and definitively understands the effect of raloxifene on apolipoprotein AI (Apo-AI), apolipoprotein B (APoB), lipoprotein (a) (Lp (a)), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in postmenopausal women.</div></div><div><h3>Methods</h3><div>A systematic literature search was conducted using scientific databases including PubMed, Scopus, Embase, and Web of Science and the Cochrane Library, through May 2024. The quality of studies was assessed using Cochrane tool. Random-effects meta-analysis was used to pool standardized mean differences (SMD) and 95 % CI for the outcomes.</div></div><div><h3>Results</h3><div>Twenty trials, with interventions ranging from 6 to 144 weeks and 2825 participants, were included. Raloxifene supplementation demonstrated significant reductions in ApoB (SMD: −0.92; 95 % CI: −1.49 to −0.35; P = 0.001), and Lp (a) (SMD: −0.25; 95 % CI: −0.39 to −0.11; P < 0.001) while increasing Apo-AI levels (SMD: 0.29; 95 % CI: 0.22–0.36; P < 0.001). Conversely, no significant effects were observed on SBP (WMD: −0.49 mmHg; 95 % CI: −3.01–2.04; P = 0.706), and DBP (WMD: −0.81 mmHg; 95 % CI: −4.04–2.41; P = 0.621). Moreover, subgroup analysis indicated that raloxifene significantly decreased DBP in studies with intervention durations of >12 weeks.</div></div><div><h3>Conclusions</h3><div>This meta-analysis has shown that raloxifene supplementation may have beneficial effects on apolipoproteins in postmenopausal women. Future studies are needed to investigate the effect of raloxifene on health status in in postmenopausal women.</div></div>\",\"PeriodicalId\":21161,\"journal\":{\"name\":\"Prostaglandins & other lipid mediators\",\"volume\":\"175 \",\"pages\":\"Article 106912\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2024-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Prostaglandins & other lipid mediators\",\"FirstCategoryId\":\"99\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1098882324001060\",\"RegionNum\":3,\"RegionCategory\":\"生物学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Prostaglandins & other lipid mediators","FirstCategoryId":"99","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1098882324001060","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

介绍：多项研究表明，补充雷洛昔芬可改善脂蛋白和血压，但其他研究结果却相互矛盾。因此，本研究旨在准确、明确地了解雷洛昔芬对绝经后妇女的载脂蛋白 AI（Apo-AI）、载脂蛋白 B（APoB）、脂蛋白（a）（Lp（a））、收缩压（SBP）和舒张压（DBP）的影响：利用科学数据库（包括 PubMed、Scopus、Embase、Web of Science 和 Cochrane 图书馆）进行了系统性文献检索，检索期至 2024 年 5 月。研究质量采用 Cochrane 工具进行评估。随机效应荟萃分析用于汇集结果的标准化均值差异（SMD）和 95% CI：共纳入了 20 项试验，干预时间从 6 周到 144 周不等，共有 2825 名参与者。雷洛昔芬补充剂可显著降低载脂蛋白B（SMD：-0.92；95% CI：-1.49至-0.35；P = 0.001）和脂蛋白（a）（SMD：-0.25；95% CI：-0.39至-0.11；P <0.001），同时提高载脂蛋白AI水平（SMD：0.29；95% CI：0.22至0.36；P <0.001）。相反，对 SBP（WMD：-0.49mmHg；95% CI：-3.01 至 2.04；P = 0.706）和 DBP（WMD：-0.81mmHg；95% CI：-4.04 至 2.41；P = 0.621）未观察到明显影响。此外，亚组分析表明，在干预时间超过12周的研究中，雷洛昔芬能显著降低DBP：这项荟萃分析表明，补充雷洛昔芬可对绝经后妇女的脂蛋白产生有益影响。今后还需要开展研究，探讨雷洛昔芬对绝经后妇女健康状况的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

The effect of raloxifene supplementation on blood pressure and Apo-lipoproteins in postmenopausal women: A systematic review and meta-analysis

Introduction

Several studies indicated the ameliorating effects of raloxifene supplementation on apolipoproteins and blood pressure, although others have conflicting findings. Therefore, the present study was conducted in order to accurately and definitively understands the effect of raloxifene on apolipoprotein AI (Apo-AI), apolipoprotein B (APoB), lipoprotein (a) (Lp (a)), systolic blood pressure (SBP) and diastolic blood pressure (DBP) in postmenopausal women.

Methods

A systematic literature search was conducted using scientific databases including PubMed, Scopus, Embase, and Web of Science and the Cochrane Library, through May 2024. The quality of studies was assessed using Cochrane tool. Random-effects meta-analysis was used to pool standardized mean differences (SMD) and 95 % CI for the outcomes.

Results

Twenty trials, with interventions ranging from 6 to 144 weeks and 2825 participants, were included. Raloxifene supplementation demonstrated significant reductions in ApoB (SMD: −0.92; 95 % CI: −1.49 to −0.35; P = 0.001), and Lp (a) (SMD: −0.25; 95 % CI: −0.39 to −0.11; P < 0.001) while increasing Apo-AI levels (SMD: 0.29; 95 % CI: 0.22–0.36; P < 0.001). Conversely, no significant effects were observed on SBP (WMD: −0.49 mmHg; 95 % CI: −3.01–2.04; P = 0.706), and DBP (WMD: −0.81 mmHg; 95 % CI: −4.04–2.41; P = 0.621). Moreover, subgroup analysis indicated that raloxifene significantly decreased DBP in studies with intervention durations of >12 weeks.

Conclusions

This meta-analysis has shown that raloxifene supplementation may have beneficial effects on apolipoproteins in postmenopausal women. Future studies are needed to investigate the effect of raloxifene on health status in in postmenopausal women.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Prostaglandins & other lipid mediators 生物-生化与分子生物学

CiteScore

5.80

自引率

3.40%

发文量

审稿时长

2 months

期刊介绍： Prostaglandins & Other Lipid Mediators is the original and foremost journal dealing with prostaglandins and related lipid mediator substances. It includes basic and clinical studies related to the pharmacology, physiology, pathology and biochemistry of lipid mediators. Prostaglandins & Other Lipid Mediators invites reports of original research, mini-reviews, reviews, and methods articles in the basic and clinical aspects of all areas of lipid mediator research: cell biology, developmental biology, genetics, molecular biology, chemistry, biochemistry, physiology, pharmacology, endocrinology, biology, the medical sciences, and epidemiology. Prostaglandins & Other Lipid Mediators also accepts proposals for special issue topics. The Editors will make every effort to advise authors of the decision on the submitted manuscript within 3-4 weeks of receipt.